| Stephen W Merriam, MD | |
|
5792 Widewaters Pkwy, Syracuse, NY 13214-1847 | |
| (315) 422-4412 | |
| (315) 422-4432 |
| Full Name | Stephen W Merriam |
|---|---|
| Gender | Male |
| Speciality | Ophthalmology |
| Experience | 23 Years |
| Location | 5792 Widewaters Pkwy, Syracuse, New York |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1013984681 | NPI | - | NPPES |
| 34628900 | Medicaid | WI |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207W00000X | Ophthalmology | 47874 (Wisconsin) | Secondary |
| 207W00000X | Ophthalmology | 227900 (New York) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| University Hospital S U N Y Health Science Center | Syracuse, NY | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Ophthalmology Medical Service Group Inc | 0446248033 | 29 |
News Archive
The legislation would expand health, education and other benefits for vets and would cost $21 billion over 10 years.
The changing healthcare landscape has pushed the medical affairs function into roles involving clinical development, regulatory compliance and market education.
3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced it has entered into an exclusive license with DiNonA Inc. for the development, manufacturing and marketing of Leukotuximab, an anti JL-1 antibody for acute leukemia (AL), including acute myelocytic leukemia (AML) and acute lymphoblastic leukemia (ALL), in the territory of Greater China (including Mainland China, Taiwan, Hong Kong and Macau) and the Middle East (excluding Cyprus, Egypt, Israel and Turkey).
Researchers with the U.S. Department of Energy's Lawrence Berkeley National Laboratory and the University of California at Berkeley have developed a new technique for magnetic resonance imaging (MRI) that allows for detection of signals from molecules present at 10,000 times lower concentrations than conventional MRI techniques.
The Arizona Republic on Friday examined how the practice of health insurers rescinding and canceling the health care policies of beneficiaries has been "scrutinized from California to Connecticut with some states passing tough measures or pursuing regulatory actions and assessing fines to restrict these retroactive health policy voids."
› Verified 7 days ago
| Entity Name | Ophthalmology Medical Service Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1225072051 PECOS PAC ID: 0446248033 Enrollment ID: O20040503001408 |
News Archive
The legislation would expand health, education and other benefits for vets and would cost $21 billion over 10 years.
The changing healthcare landscape has pushed the medical affairs function into roles involving clinical development, regulatory compliance and market education.
3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced it has entered into an exclusive license with DiNonA Inc. for the development, manufacturing and marketing of Leukotuximab, an anti JL-1 antibody for acute leukemia (AL), including acute myelocytic leukemia (AML) and acute lymphoblastic leukemia (ALL), in the territory of Greater China (including Mainland China, Taiwan, Hong Kong and Macau) and the Middle East (excluding Cyprus, Egypt, Israel and Turkey).
Researchers with the U.S. Department of Energy's Lawrence Berkeley National Laboratory and the University of California at Berkeley have developed a new technique for magnetic resonance imaging (MRI) that allows for detection of signals from molecules present at 10,000 times lower concentrations than conventional MRI techniques.
The Arizona Republic on Friday examined how the practice of health insurers rescinding and canceling the health care policies of beneficiaries has been "scrutinized from California to Connecticut with some states passing tough measures or pursuing regulatory actions and assessing fines to restrict these retroactive health policy voids."
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Stephen W Merriam, MD 5792 Widewaters Pkwy, Syracuse, NY 13214-1847 Ph: (315) 422-4412 | Stephen W Merriam, MD 5792 Widewaters Pkwy, Syracuse, NY 13214-1847 Ph: (315) 422-4412 |
News Archive
The legislation would expand health, education and other benefits for vets and would cost $21 billion over 10 years.
The changing healthcare landscape has pushed the medical affairs function into roles involving clinical development, regulatory compliance and market education.
3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced it has entered into an exclusive license with DiNonA Inc. for the development, manufacturing and marketing of Leukotuximab, an anti JL-1 antibody for acute leukemia (AL), including acute myelocytic leukemia (AML) and acute lymphoblastic leukemia (ALL), in the territory of Greater China (including Mainland China, Taiwan, Hong Kong and Macau) and the Middle East (excluding Cyprus, Egypt, Israel and Turkey).
Researchers with the U.S. Department of Energy's Lawrence Berkeley National Laboratory and the University of California at Berkeley have developed a new technique for magnetic resonance imaging (MRI) that allows for detection of signals from molecules present at 10,000 times lower concentrations than conventional MRI techniques.
The Arizona Republic on Friday examined how the practice of health insurers rescinding and canceling the health care policies of beneficiaries has been "scrutinized from California to Connecticut with some states passing tough measures or pursuing regulatory actions and assessing fines to restrict these retroactive health policy voids."
› Verified 7 days ago
Dr. George Salloum, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 750 E Adams St, Syracuse, NY 13210 Phone: 315-464-5230 | |
Charles Teitelbaum, MD Ophthalmology Medicare: Medicare Enrolled Practice Location: 5792 Widewaters Pkwy Ste 101, Syracuse, NY 13214 Phone: 315-422-4412 | |
Dr. Michael J Geiss Iii, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 2215 E Genesee St, Syracuse, NY 13210 Phone: 315-472-5329 Fax: 315-472-3211 | |
Preethi Ganapathy, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 550 Harrison St Ste L, Syracuse, NY 13202 Phone: 315-464-5253 | |
Dr. Adam Miller, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 5792 Widewaters Pkwy Ste 101, Syracuse, NY 13214 Phone: 315-422-4412 | |
Evis Petrela, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 4900 Broad Rd, Suite 3p, Syracuse, NY 13215 Phone: 315-492-5910 Fax: 315-492-5950 |